Informed Prostate Cancer Patient Support

Revolutionary Breakthrough: Remote Robotic Surgery Brings World-Class Prostate Cancer Care Across Continents A comprehensive update for the Informed Prostate Cancer Support Group Newsletter The Dawn of Transcontinental Surgery The field of prostate cancer treatment has witnessed a revolutionary milestone with the successful completion of multiple remote robotic surgeries using 5G networks and advanced robotic systems. This breakthrough technology promises to democratize access to world-class surgical expertise, potentially transforming care delivery for prostate cancer patients worldwide. The Critical Need for Remote Surgical Expertise The geographic distribution of prostate cancer patients creates a fundamental challenge in modern healthcare delivery. While prostate cancer affects men globally, highly skilled robotic surgeons capable of performing complex procedures are concentrated in major urban medical centers, often thousands of miles away from patients who need the...

Major Advances in PSMA-Targeted Therapy and Veterans Research Take Center Stage Carlsbad, CA – The 31st Annual Prostate Cancer Foundation (PCF) Scientific Retreat, held October 24-26, 2024, at the Omni La Costa Resort, brought together leading prostate cancer researchers from around the world to share groundbreaking discoveries and forge new collaborative pathways toward a cure. About the Scientific Retreat Since 1993, PCF has hosted this annual gathering, which has become the foremost scientific conference in the world on the biology and treatment of prostate cancer. The diversity, novelty, and extremely high impact of the topics presented, along with the excellence of the invited attendees, make this a unique conference that reflects PCF's unyielding commitment to ending death and suffering from prostate cancer. This year's retreat featured specialized programs including the PCF Young Investigator Forum (October 23) for 2020-2024 PCF Young Investigators and...

Groundbreaking Korean Study Adds International Evidence to Support Active Surveillance Bottom Line First A major new study from Korea provides reassuring evidence that active surveillance/watchful waiting (AS/WW) is as safe as surgery or radiation for men with localized prostate cancer, with survival rates exceeding 99% across all treatment approaches over 4.4 years of follow-up. The Study at a Glance Researchers from multiple Korean institutions, including Ajou University and Stanford University, published groundbreaking results in July 2025 that should provide significant comfort to men considering active surveillance for their prostate cancer diagnosis. What They Found: Excellent survival rates across all treatments : 99.8% survived prostate cancer specifically, and 98.8% survived from all causes No significant difference in mortality between active surveillance, surgery (prostatectomy), or radiation therapy Comparable metastasis rates among all three approaches Lo...

Beyond the Numbers: Why PSA Levels Need Context, Not Panic A Modern Approach to Understanding Your Prostate Cancer Risk Bottom Line Up Front: Recent research confirms that PSA levels alone shouldn't determine your prostate cancer risk. New tools combining PSA with advanced biomarkers and MRI are revolutionizing how doctors assess which men truly need biopsies, potentially reducing unnecessary procedures by up to 40% while catching aggressive cancers more accurately. The Phone Call That Changes Everything "My PSA came back at 6.2 — does that mean I have cancer?" For too many men, this question triggers a cascade of anxiety that can last weeks or months. As Dr. Martina Ambardjieva, a urologist specializing in oncology, recently wrote, this scenario plays out in clinics worldwide every day. But here's what's changing: the medical community is moving away from the rigid, one-size-fits-all approach to PSA interpretation that has dominated prostate can...

(a) Time to treatment failure. The median time to treatment failure was longest in the ENZ group compared with ABI and DOC (ENZ vs. ABI vs. DOC: 25.0 vs. 21.0 vs. 10.0 months; p  < 0.0001). The hazard ratio (HR) for ENZ vs. ABI was 0.841 ( p  < 0.0001), and for ABI vs. DOC was 0.558 ( p  < 0.0001).  (b) Overall Survival in all patients with CRPC. The median overall survival was 71 months in both the ENZ and ABI groups, and 60 months in the DOC group. ENZ vs. ABI showed a statistically significant difference (HR: 0.903; p  = 0.003), as did ABI vs. DOC (HR: 0.718; p  < 0.0001). ABI, abiraterone acetate; DOC, docetaxel; ENZ, enzlutamide. [Color figure can be viewed at wileyonlinelibrary.com ] Major Japanese Study Provides New Insights on First-Line CRPC Treatment: Enzalutamide vs. Abiraterone vs. Docetaxel What This Means for You: New evidence helps guide treatment decisions for castration-resistant prostate cancer By: Medical Editor, IPCSG Newsletter A groundbreak...